Andere Sprachen SymBio Pharmaceuticals Limited

Aktien

A1JMJE

JP3383050006

4582

Verzögert Japan Exchange Andere Börsenplätze 02:25:40 02.05.2024			% 5 Tage	% 1. Jan.
173 ^JPY	-0,57 %		-3,89 %	-29,96 %

13.02.	SymBio Pharmaceutical's FY2023 Ergebnis verfehlt Prognose aufgrund eines höher als erwarteten operativen Verlustes	MT
08.02.	SymBio Pharmaceuticals Limited gibt Gewinnprognose für das Geschäftsjahr 2024 ab	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	19.04.
SymBio Pharmaceuticals Limited amended terms of the transaction	18.03.
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	13.02.
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	08.02.
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	08.02.
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	08.02.
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	15.11.
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	14.11.
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	14.11.
SymBio Pharmaceuticals Limited amended terms of the transaction	10.11.
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	06.10.23
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	03.08.23
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	03.08.23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	27.04.23
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27.04.23
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	25.04.23
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	24.04.23
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	22.03.23
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	16.03.23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SymBio Pharmaceuticals Limited

Aktien

A1JMJE

JP3383050006

4582

Andere Sprachen

Filter